CRSP CRISPR Therapeutics AGcompanySEC Filings & Insider Trading Activity 2026
Latest CRISPR Therapeutics AG (CRSP) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 12, 2026, a 10-Q quarterly report filed on November 10, 2025, an 8-K current report filed on March 16, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for CRISPR Therapeutics AG (CRSP) (SEC CIK 1674416), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- • New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
Risk Factors
- • Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- • Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
Management Discussion & Analysis
- • No revenue or YoY revenue figures disclosed for 2025 vs 2024
- • Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New regulatory risk: ongoing U.S. government shutdown since Oct 1, 2025 causing FDA, SEC furloughs and layoffs impacting product review timelines
- • Updated regulatory risk: potential prolonged delays in FDA's IND submissions and drug approvals due to staffing cuts and disrupted operations
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Convertible notes sold via Rule 144A private placement to qualified institutional buyers — no public registration, limiting secondary market liquidity
- • Purchase agreement dated March 10, 2026 between CRISPR Therapeutics and initial purchasers — conversion into common shares exempt under Securities Act Section 3(a)(9)
Item 8.01: Other Events
- • Priced $550M convertible senior notes due 2031, upsized from initial $350M offering — 57% increase signals strong institutional demand
- • Private placement via Rule 144A, sold only to qualified institutional buyers — no SEC registration, limits retail participation
Annual Reports Archive10-K
AI-powered analysis of CRISPR Therapeutics AG (CRSP) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of CRISPR Therapeutics AG (CRSP) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of CRISPR Therapeutics AG (CRSP) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $1.2M | $371.2M | $37.3M | $3.5M |
| Operating Income | -$673.2M | -$222.5M | -$466.6M | -$664.6M |
| Net Income | -$650.2M | -$153.6M | -$366.3M | -$581.6M |
| Op. Margin | -56190.4% | -60.0% | -1250.4% | -18933.6% |
| Net Margin | -54271.7% | -41.4% | -981.5% | -16569.8% |
| Balance Sheet | ||||
| Total Assets | $2.2B | $2.2B | $2.2B | $2.3B |
| Equity | $1.9B | $1.9B | $1.9B | $1.9B |
| ROE | -34.7% | -8.2% | -19.0% | -30.3% |
Source: XBRL financial data from CRISPR Therapeutics AG (CRSP) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 16, 2026 | — | Analysis | — |
8-K | Mar 11, 2026 | — | Analysis | — |
8-K | Feb 12, 2026 | — | — | |
10-K | Feb 12, 2026 | Dec 31, 2025 | Analysis | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 10, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 4, 2025 | Jun 30, 2025 | — | |
10-Q | May 6, 2025 | Mar 31, 2025 | — | |
10-K | Feb 11, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 5, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 5, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-K | Feb 21, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 7, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-K | Feb 21, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 1, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-K | Feb 15, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 29, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 27, 2021 | Mar 31, 2021 | — | |
10-K | Feb 16, 2021 | Dec 31, 2020 | — |
Frequently Asked Questions
What are the latest CRSP SEC filings in 2026?
CRISPR Therapeutics AG (CRSP) has filed a 10-K annual report on February 12, 2026, a 10-Q quarterly report on November 10, 2025, an 8-K current report on March 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did CRSP file its most recent 10-K annual report?
CRISPR Therapeutics AG (CRSP) filed its most recent 10-K annual report on February 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view CRSP 10-Q quarterly reports?
CRISPR Therapeutics AG (CRSP)'s most recent 10-Q quarterly report was filed on November 10, 2025. SignalX displays every CRSP 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CRSP filed recently?
CRISPR Therapeutics AG (CRSP)'s most recent 8-K was filed on March 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CRSP insider trading activity (Form 4)?
SignalX aggregates every CRSP Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CRSP file with the SEC?
CRISPR Therapeutics AG (CRSP) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CRSP filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for CRISPR Therapeutics AG (CRSP).
What is CRSP's SEC CIK number?
CRISPR Therapeutics AG (CRSP)'s SEC CIK (Central Index Key) number is 1674416. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1674416 to look up all CRSP filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CRSP return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from CRISPR Therapeutics AG (CRSP) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of CRISPR Therapeutics AG SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 42+ filings.